Ra Pharmaceuticals (NASDAQ:RARX) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Monday, February 4th.
Several other research analysts also recently weighed in on the company. Jefferies Financial Group boosted their price target on Ra Pharmaceuticals to $40.00 and gave the company a “positive” rating in a report on Monday, December 10th. SunTrust Banks boosted their price target on Ra Pharmaceuticals to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 11th. BMO Capital Markets set a $34.00 price target on Ra Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 10th. Raymond James upgraded Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 price target for the company in a report on Wednesday, October 10th. Finally, BidaskClub upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 19th. One analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $34.63.
Shares of RARX opened at $19.49 on Monday. The firm has a market capitalization of $626.58 million, a price-to-earnings ratio of -8.09 and a beta of 0.90. Ra Pharmaceuticals has a fifty-two week low of $4.78 and a fifty-two week high of $23.90.
In related news, Director Ra Capital Healthcare Fund Lp acquired 1,006,452 shares of the stock in a transaction dated Wednesday, December 12th. The stock was bought at an average cost of $15.50 per share, with a total value of $15,600,006.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Enterprise Associates 13 L. New purchased 645,161 shares of the firm’s stock in a transaction that occurred on Friday, December 14th. The shares were acquired at an average cost of $15.50 per share, with a total value of $9,999,995.50. The disclosure for this purchase can be found here. Insiders have bought a total of 2,658,065 shares of company stock valued at $41,200,008 over the last three months. Corporate insiders own 11.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in RARX. BlackRock Inc. boosted its position in Ra Pharmaceuticals by 33.5% during the 2nd quarter. BlackRock Inc. now owns 1,537,331 shares of the company’s stock worth $15,297,000 after purchasing an additional 385,587 shares during the period. Dimensional Fund Advisors LP boosted its position in Ra Pharmaceuticals by 27.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 214,579 shares of the company’s stock worth $2,135,000 after purchasing an additional 46,126 shares during the period. FMR LLC purchased a new stake in Ra Pharmaceuticals during the 2nd quarter worth $807,000. Bank of America Corp DE boosted its position in Ra Pharmaceuticals by 513.2% during the 2nd quarter. Bank of America Corp DE now owns 43,436 shares of the company’s stock worth $432,000 after purchasing an additional 36,352 shares during the period. Finally, First Manhattan Co. boosted its position in Ra Pharmaceuticals by 38.1% during the 3rd quarter. First Manhattan Co. now owns 1,073,906 shares of the company’s stock worth $19,426,000 after purchasing an additional 296,419 shares during the period. 83.02% of the stock is owned by hedge funds and other institutional investors.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Recommended Story: What is the return on assets (ROA) ratio?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.